271 related articles for article (PubMed ID: 27565902)
1. Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial.
Unger JM; Till C; Thompson IM; Tangen CM; Goodman PJ; Wright JD; Barlow WE; Ramsey SD; Minasian LM; Hershman DL
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27565902
[TBL] [Abstract][Full Text] [Related]
2. Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
Unger JM; Hershman DL; Till C; Tangen CM; Barlow WE; Ramsey SD; Goodman PJ; Thompson IM
J Natl Cancer Inst; 2018 Nov; 110(11):1208-1215. PubMed ID: 29534197
[TBL] [Abstract][Full Text] [Related]
3. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
[TBL] [Abstract][Full Text] [Related]
4. Clinical effects and economical impact of dutasteride and finasteride therapy in Italian men with LUTS.
Cindolo L; Berardinelli F; Fanizza C; Romero M; Pirozzi L; Tamburro FR; Pellegrini F; Neri F; Pitrelli A; Schips L
Arch Ital Urol Androl; 2013 Dec; 85(4):200-6. PubMed ID: 24399122
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival of participants in the prostate cancer prevention trial.
Thompson IM; Goodman PJ; Tangen CM; Parnes HL; Minasian LM; Godley PA; Lucia MS; Ford LG
N Engl J Med; 2013 Aug; 369(7):603-10. PubMed ID: 23944298
[TBL] [Abstract][Full Text] [Related]
6. Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial.
Murtola TJ; Gurel B; Umbehr M; Lucia MS; Thompson IM; Goodman PJ; Kristal AR; Parnes HL; Lippman SM; Sutcliffe S; Peskoe SB; Barber JR; Drake CG; Nelson WG; De Marzo AM; Platz EA
Cancer Epidemiol Biomarkers Prev; 2016 Mar; 25(3):463-9. PubMed ID: 26715424
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial.
Kaplan SA; Lee JY; Meehan AG; Kusek JW;
J Urol; 2011 Apr; 185(4):1369-73. PubMed ID: 21334655
[TBL] [Abstract][Full Text] [Related]
8. The clinical applications of five-alpha reductase inhibitors.
Loughlin KR
Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
[TBL] [Abstract][Full Text] [Related]
9. Five-alpha-reductase Inhibitors for prostate cancer prevention.
Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
Cochrane Database Syst Rev; 2008 Apr; (2):CD007091. PubMed ID: 18425978
[TBL] [Abstract][Full Text] [Related]
10. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
11. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia.
Parsons JK; Schenk JM; Arnold KB; Messer K; Till C; Thompson IM; Kristal AR; ;
Eur Urol; 2012 Aug; 62(2):234-41. PubMed ID: 22459892
[TBL] [Abstract][Full Text] [Related]
12. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia.
Zhang H; Frendl DM; Wang Z; Olumi AF
J Urol; 2020 Aug; 204(2):325-331. PubMed ID: 32167867
[TBL] [Abstract][Full Text] [Related]
13. Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial.
Nash SH; Till C; Song X; Lucia MS; Parnes HL; Thompson IM; Lippman SM; Platz EA; Schenk J
Cancer Epidemiol Biomarkers Prev; 2015 Oct; 24(10):1507-15. PubMed ID: 26269564
[TBL] [Abstract][Full Text] [Related]
14. [The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].
Schmitz-Dräger BJ; Fischer C; Bismarck E; Dörsam HJ; Lümmen G
Urologe A; 2007 Oct; 46(10):1364, 1366-8, 1370. PubMed ID: 17874228
[TBL] [Abstract][Full Text] [Related]
15. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
[TBL] [Abstract][Full Text] [Related]
16. Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.
Chu LW; Till C; Yang B; Tangen CM; Goodman PJ; Yu K; Zhu Y; Han S; Hoque AM; Ambrosone C; Thompson I; Leach R; Hsing AW
Mol Carcinog; 2018 Mar; 57(3):462-466. PubMed ID: 29318656
[TBL] [Abstract][Full Text] [Related]
17. Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial.
Resnick MJ
J Urol; 2018 Oct; 200(4):689. PubMed ID: 30227567
[No Abstract] [Full Text] [Related]
18. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.
Moinpour CM; Darke AK; Donaldson GW; Thompson IM; Langley C; Ankerst DP; Patrick DL; Ware JE; Ganz PA; Shumaker SA; Lippman SM; Coltman CA
J Natl Cancer Inst; 2007 Jul; 99(13):1025-35. PubMed ID: 17596576
[TBL] [Abstract][Full Text] [Related]
20. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
